Here is an article about Novartis betting big on T-cell treatment for blood cancers. It has a lot of interesting details about the treatment, its progress, and the potential business model for Novartis.
There's also a mention about the increased "value" of Gleevec over the years, and the possibility of the US patent expiring as soon as next summer. Very good read if you're into the details:
http://www.forbes.co...ll-cure-cancer/
